Abstract
Infliximab, manufactured as Remicade by Centocor Inc. (Malvern, Pennsylvania, USA), is the only intravenously infused biologic agent approved for the treatment of adults with chronic severe plaque-type psoriasis. The family of biologic agents currently approved for this more extensive and often times debilitating type of psoriasis includes infliximab, alefacept, efalizumab, etanercept, and adalimumab.
| Original language | English (US) |
|---|---|
| Title of host publication | Moderate-to-Severe Psoriasis, Third Edition |
| Publisher | CRC Press |
| Pages | 289-305 |
| Number of pages | 17 |
| ISBN (Electronic) | 9781420088687 |
| ISBN (Print) | 142008867X, 9781420088670 |
| State | Published - Jan 1 2008 |
| Externally published | Yes |
ASJC Scopus subject areas
- General Medicine